AI medical stock landing MASSIVE contracts

The company I'm going to tell you about today I believe will become the most important AI company in the world over the coming years. Hey Traders. From time to time, we'll share information we think you may find valuable. Please feel free to check it out below... Dear Reader, Few people know its name, but Intuitive Surgical was one of the five best stocks of the last 20 years. It went up as much as 18,000% in two decades. Why? Because it used new technology – surgical robotics – to drive sales sky high. Now... [another company is following its path](. The company is tiny today – just $500 million – but it is in position to grow dramatically. In short, it is [the inventor of the world's first AI-designed drug to enter clinical trials](. And big pharma is lining up to use its patent-protected technology. - Merck is collaborating with them on three projects that could generate up to $674 million in revenue. - French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs. - Bristol Meyers Squibb signed a $1.2 billion partnership with the company. You can see... each one of these projects is worth more than the entire market cap of this new AI stock! In short, the upside is MASSIVE. Which is why I wanted to send you [this video](. [Play Now: The #1 AI Stock]( It comes from one of the great stock pickers of all-time – a man who actually recommended Intuitive Surgical in real time back in 2004. In fact, he called 4 of the top 6 performing stocks from 2000 to 2020. And he says this new company is the #1 AI Stock Under $10. [Watch his free video breaking down the situation here.]( Sincerely, Rachel Gearhart Associate Publisher, The Oxford Club --------------------------------------------------------------- This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201. If you would like to opt-out from receiving offers from The Oxford Club please [click here](. Financhill Disclaimer: This is a sponsored message. This is not an endorsement for any product or service. Financhill is not a licensed financial advisor. The content on any Financhill websites, products or communication is for educational purposes only. Trading stocks, options and other securities involves risk and the risk of loss can be substantial. Past performance is no guarantee of future performance. You can see our full disclaimer [here]( and our terms [here](. This email was sent to {EMAIL}. Don't want to receive these emails anymore? [Unsubscribe]( Financhill, PO Box Box 126 Catasauqua PA 18032